Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of
Rgenix Names Industry Veteran to Chief Medical Officer Role
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry. Wasserman will oversee new Phase 1b/2 trial of lead compound RGX-104 in lung cancer patients; and RGX-202
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of RGX-019 FOR IMMEDIATE RELEASE New York, NY – April 3, 2019 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
New York, NY – April 1, 2019- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s
Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System
Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019 Masoud Tavazoie, Rgenix CEO and Co-Founder speaks at Immuno-Oncology 360° In its 5th year, the IO360 conference brings together diverse stakeholders of drug development in immuno-oncology (IO). The
Xconomy: New York Biotech – How to make it here
6:15-6:45 PM | The Rgenix Story: From our beginnings as a small spin-out from Rockefeller University to a world-class team with multiple clinical programs and $40M in Series C funding, our executives tell the story of our Manhattan-based biotechnology company. Masoud Tavazoie - CEO,
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and Immunotherapy conference in Miami, Fl. As part of his presentation, Masoud described the LXR/ApoE pathway and its role in regulating the innate
AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 - 30, 2018 | Loews Miami Beach Hotel, Miami Beach, Florida, USA Wednesday, Nov. 28 - Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy Session Chair: Matthew G. Vander Heiden, David H. Koch Institute